1.
|
9 p, 325.6 KB |
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study
/
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ;
Lenz, H. J. (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ;
Lonardi, Sara (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ;
Falcone, Alfredo (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ;
Limón, M. L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Saunders, M. (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ;
Sobrero, A. (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ;
Park, Y S. (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ;
Ferreiro, R. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Hong, Y S. (Department of Oncology, Asan Medical Center, Seoul, South Korea) ;
Tomasek, J. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Taniguchi, H. (Aichi Cancer Center Hospital) ;
Ciardiello, Fortunato (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ;
Stoehr, J. (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ;
Oum'Hamed, Z. (Boehringer Ingelheim France S.A.S, Reims, France) ;
Vlassak, S. (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ;
Studeny, M. (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ;
Argiles, G.. (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963
|
|